Pulse Biosciences, Inc.
Pulse Biosciences, Inc. (Nasdaq: PLSE) develops medical devices using its patented Nano-pulse Stimulation (NPS) technology, which delivers nanosecond electrical pulses to ablate targeted cells without thermal injury. Its nPulse platform supports the Vybrance Percutaneous Electrode System for soft-tissue ablation and… From the company’s description.
Over the twelve months to Sep 30, 2026, Pulse Biosciences, Inc. reported revenue of $1.49M, up 1637.2% from a year earlier, and a net loss of $83.72M. Operations used $63.33M in cash. In fiscal 2025, it reported revenue of $0.35M and a net loss of $72.78M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Pulse Biosciences, Inc. does
In the company’s own words
Pulse Biosciences, Inc. (Nasdaq: PLSE) develops medical devices using its patented Nano-pulse Stimulation (NPS) technology, which delivers nanosecond electrical pulses to ablate targeted cells without thermal injury. Its nPulse platform supports the Vybrance Percutaneous Electrode System for soft-tissue ablation and devices in development for treating atrial fibrillation, including a surgical clamp and an endocardial catheter. The company’s customers and clinical users include surgeons, electrophysiologists, and other physicians; its Vybrance system has FDA 510(k) clearance, while its cardiac products are in clinical development. Pulse previously commercialized the nPulse system for dermatologic procedures, but shifted its focus in 2022 to cardiology and soft-tissue ablation. It continues to support remaining dermatology users and may pursue partnerships for that application. The company had 116 employees as of December 31, 2025, with half engaged in research and development. Its website is www.pulsebiosciences.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- HAYWARD, CA
- Fiscal year end
- December
- CIK
- 1625101
- SIC
- 3841
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Pulse Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Pulse Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Pulse Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Pulse Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Pulse Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”